These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 18035802)

  • 1. Predisposing factors for nevirapine toxicity among AIDS patients with low baseline CD4 count.
    Tansuphaswadikul S; Aung SE; Phonrat B; Kaewkungwal J; Pitisuttithum P; Maek-a-nantawat W
    Asian Pac J Allergy Immunol; 2007; 25(2-3):147-54. PubMed ID: 18035802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
    Manosuthi W; Mankatitham W; Lueangniyomkul A; Chimsuntorn S; Sungkanuparph S
    HIV Med; 2008 May; 9(5):294-9. PubMed ID: 18400076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nevirapine-related adverse events among children switched from efavirenz to nevirapine as compared to children who were started on nevirapine-based antiretroviral therapy directly.
    Sanjeeva GN; Sukanya V; Pavithra HB; Dodderi SK; Rewari BB; Govindaraj M; Shivananda S; Premalatha R
    AIDS Care; 2015; 27(5):655-9. PubMed ID: 25517472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
    Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash.
    Kiertiburanakul S; Malathum K; Watcharananan S; Sathapatayavongs B; Sungkanuparph S
    Int J STD AIDS; 2009 Mar; 20(3):176-9. PubMed ID: 19255265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
    Bonnet M; Bhatt N; Baudin E; Silva C; Michon C; Taburet AM; Ciaffi L; Sobry A; Bastos R; Nunes E; Rouzioux C; Jani I; Calmy A;
    Lancet Infect Dis; 2013 Apr; 13(4):303-12. PubMed ID: 23433590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.
    João EC; Calvet GA; Menezes JA; D'Ippolito MM; Cruz ML; Salgado LA; Matos HJ
    Am J Obstet Gynecol; 2006 Jan; 194(1):199-202. PubMed ID: 16389032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study.
    Manosuthi W; Chumpathat N; Chaovavanich A; Sungkanuparph S
    BMC Infect Dis; 2005 Aug; 5():67. PubMed ID: 16120209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of nevirapine-treated patients in a single-centre cohort.
    Colafigli M; Di Giambenedetto S; Bracciale L; Fanti I; Prosperi M; Cauda R; De Luca A
    HIV Med; 2009 Sep; 10(8):461-9. PubMed ID: 19459991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.
    Hermans SM; Manabe YC; Kiragga AN; Hoepelman AI; Lange JM; van Leth F
    Antivir Ther; 2013; 18(4):615-22. PubMed ID: 23423604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine.
    Martín-Carbonero L; Núñez M; González-Lahoz J; Soriano V
    HIV Clin Trials; 2003; 4(2):115-20. PubMed ID: 12671779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication.
    Aaron E; Kempf MC; Criniti S; Tedaldi E; Gracely E; Warriner A; Kumar R; Bachmann LH
    PLoS One; 2010 Sep; 5(9):e12617. PubMed ID: 20838641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/microL.
    Manosuthi W; Sungkanuparph S; Tansuphaswadikul S; Chottanapund S; Mankatitham W; Chimsuntorn S; Sittibusaya C; Moolasart V; Chaovavanich A
    J Med Assoc Thai; 2008 Feb; 91(2):159-65. PubMed ID: 18389979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/microL.
    Manosuthi W; Sungkanuparph S; Tansuphaswadikul S; Inthong Y; Prasithsirikul W; Chottanapund S; Mankatitham W; Chimsuntorn S; Sittibusaya C; Moolasart V; Chumpathat N; Termvises P; Chaovavanich A
    Int J STD AIDS; 2007 Nov; 18(11):782-6. PubMed ID: 18005514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients.
    de Beaudrap P; Etard JF; Guèye FN; Guèye M; Landman R; Girard PM; Sow PS; Ndoye I; Delaporte E;
    AIDS Res Hum Retroviruses; 2008 Jun; 24(6):753-60. PubMed ID: 18507521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4 count and risk of anti-tuberculosis drug-associated cutaneous reactions in HIV-infected Thai patients.
    Boonyagars L; Hirunwiwatkul P; Hurst CP
    Int J Tuberc Lung Dis; 2017 Mar; 21(3):338-344. PubMed ID: 28225346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy.
    van Griensven J; Choun K; Chim B; Thai S; Lorent N; Lynen L
    Trop Med Int Health; 2015 Dec; 20(12):1823-31. PubMed ID: 26426387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
    Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nevirapine-associated hepatotoxicity and rash among HIV-infected pregnant women in Kenya.
    Peters PJ; Polle N; Zeh C; Masaba R; Borkowf CB; Oyaro B; Omolo P; Ogindo P; Ndivo R; Angira F; Lando R; Fowler MG; Weidle PJ; Thomas TK
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(2):142-9. PubMed ID: 22020069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients.
    Bonjoch A; Paredes R; Domingo P; Cervantes M; Pedrol E; Ribera E; Force L; Llibre JM; Vilaró J; Dalmau D; Cucurull J; Mascaró J; Masabeu A; Pérez-Alvarez N; Puig J; Cinquegrana D; Clotet B
    AIDS Res Hum Retroviruses; 2006 Apr; 22(4):321-9. PubMed ID: 16623634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.